Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| CXMT | Alibaba Group | Pfizer | |
|---|---|---|---|
| Moat rating | none CXMT's 2026 interim report (published 2026-08-29) names scale and IDM technology as core competencies, but also concedes gaps. It says that compared with the leading international manufacturers the Company 'still has a certain gap in overall scale, technology accumulation and customer resources' (与国际头部厂商相比，公司在整体规模、技术积累、客户资源等方面仍然存在一定差距). It describes its scale effect as 'gradually emerging' (逐步显现), and its gross-margin risk covers the case where the scale effect cannot materialise over the long term (公司规模效应长期无法显现). Its excess returns span a single shortage. The retained-earnings note shows an accumulated deficit of ¥36.65bn entering 2026, after ¥1.87bn of 2025 net profit attributable to the parent, and the first-half 2025 net loss attributable to shareholders was ¥2.33bn. Then first-half 2026 revenue rose 873.64%, which the report attributes to the global DRAM supply shortage, higher prices and sharply higher volumes, and the main-business gross margin reached 84.84%. | wide The FY2026 20-F rests on two entrenched positions: a commerce ecosystem the filing ties to 'the world's largest online retail market' with 'over 1.1 billion Internet users,' and a cloud business whose 'Cloud Intelligence Group's external revenue growth accelerated to 40% in the final quarter of fiscal 2026, with AI-related products accounting for 30% of this revenue.' Two durable franchises under one roof is a wide moat — bounded by China regulation and US ICTS cloud controls the same filing flags. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none On the report's own evidence, no candidate moat source qualifies. Cost scale: the report calls DRAM a highly standardised product (高度标准化的产品) in which the cost advantage of scale is a core competency. But CXMT ranks fourth globally by capacity, and the report, calculating on sales, puts Samsung, SK hynix and Micron at 33.96%, 34.48% and 23.41% of the 2025 global DRAM market, so the scale advantage lies with the leaders. IP: it reports 4,484 domestic patents (3,744 of them invention patents) and 3,400 overseas patents as of 2026-06-30. Yet it describes its core technology as reaching 'international advanced level' (国际先进水平) and flags possible IP disputes with competitors. Switching costs: ¥133.48bn of ¥150.31bn first-half 2026 revenue went through distributors, who under the report's revenue note decide their own resale prices. | network effects The 20-F names 'the network effects of our ecosystems' among the factors its business depends on: Taobao and Tmall, Alipay, Amap and the rest compound as buyers, sellers and services reinforce each other across one integrated ecosystem. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower TrendForce (2026-09-24) reports that CXMT's global DRAM revenue share rose to 9.5% in 2Q26 from 7.6% in 1Q26, 'placing it fourth behind Samsung at 39.4%, SK hynix at 24.9%, and Micron at 23.3%'. It is catching up through generation-skipping R&D. The interim report had its fifth process platform in customer certification, and a voluntary disclosure on 2026-09-21 announced that platform's mass production, adding that its products are not yet in scale sales and yields need time to ramp. TrendForce's listing analysis (2026-07-28) still says CXMT 'still trails Samsung, SK hynix, and Micron in advanced processes, product performance, yields, and certification by high-end customers'. | clear leader The 20-F claims leadership in applied AI ('strengthened our leadership in applied AI') and roots the commerce business in the world's largest online retail market; Alibaba Cloud is the leading China hyperscaler pivoting to AI, per the segment discussion — a category leader in both its home markets. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak CXMT is a price taker riding the cycle. The interim report attributes first-half revenue growth to the global DRAM supply shortage, rising prices and sharply higher volumes. It records industry prices between 2015 and 2025 as high as $7.89/GB and as low as $1.78/GB in first-half 2023, and it states that the continued steep price rise is not sustainable. Main-business revenue was ¥15.22bn against cost of ¥13.29bn in first-half 2025, and ¥150.04bn against ¥22.75bn in first-half 2026. Most sales go through distributors, who set their own resale prices. | moderate Ecosystem lock-in and cloud scale support pricing, but the filing warns that if 'user activity and engagement in our ecosystem may decrease … our market share and profitability may be negatively affected,' and Chinese e-commerce/cloud competition is intense — real but capped pricing power. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | CXMT (ChangXin) is a Hefei-based IDM that designs and fabricates DDR5 and LPDDR4X/LPDDR5/5X/LPDDR6 memory and sells DRAM wafers, chips and modules. Its 2026 interim report says it reached its fourth process platform through a 'generation-skipping' (跳代研发) R&D strategy, and that it ranks first in China and fourth globally by shipments and sales. First-half 2026 revenue was ¥150.31bn (DDR series ¥69.47bn, LPDDR series ¥78.19bn), with a main-business gross margin of 84.84%. TrendForce puts its 2Q26 DRAM revenue share at 9.5%, up from 7.6% in 1Q26. The position is real but recent. The report concedes gaps to the three leaders in scale, technology and customers. The customers it names are Alibaba Cloud, ByteDance, Tencent, Lenovo, Xiaomi, Transsion, Honor, OPPO and vivo. On 2026-06-08 the US Defense Department added its subsidiary ChangXin Memory to the Section 1260H list. TrendForce notes that export controls leave CXMT relying on DUV multiple patterning rather than EUV, and that its prospectus 'has not disclosed a clear mass-production timetable' for HBM. The report itself warns that the continued steep rise in DRAM prices is not sustainable (价格的持续大幅上涨不具备可持续性) as international makers add capacity. | Alibaba is a commerce network and an AI cloud fused into one ecosystem. The retail side draws its moat from network effects the filing names explicitly, rooted in the world's largest online retail market; the cloud side is pivoting hard into AI — Alibaba Cloud's 'growth engine fully pivots from traditional compute and storage to models, AI compute, and agent services,' anchored by the in-house Qwen family (Qwen3.7-Max 'specifically engineered for agents') and the PAI platform. The 20-F's own framing is 'leading full-stack capabilities across the AI value chain.' The counterweights are structural rather than competitive: a Cayman VIE structure, China's regulatory environment, and the US Commerce Department's proposed ICTS cloud-computing controls the filing discloses. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream DRAM IDM selling wafers, chips and modules to server, smartphone, PC and automotive makers, mostly through distributors (¥133.48bn of ¥150.31bn first-half 2026 revenue). | Layer-8 hyperscaler + AI-application incumbent: Alibaba Cloud supplies AI compute and the Qwen models while the commerce ecosystem is a vast applied-AI distribution surface. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |